N@N

More Than 260 Presentations and Posters Evaluating Celgene Products to Be Highlighted at the 52nd American Society of Hematolog

^{Published on 2010-11-30 04:46:06 - Market Wire}
 

BOUDRY, Switzerland--([ BUSINESS WIRE ])--Celgene International Srl (NASDAQ: CELG) today announced that clinical investigators from leading cancer research centers will present data from recent and on-going clinical trials in more than 260 posters and presentations, including more than 65 oral presentations evaluating Celgene products in blood cancers at the 52^nd American Society of Hematology Annual Meeting in Orlando, Florida from December 4-7.

For more information, please visit [ www.hematology.org ].

About Celgene International Srl

Celgene International Srl, located in Boudry, in the Canton of Neuchtel, Switzerland, is a wholly owned subsidiary and international headquarters of Celgene Corporation. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the Company's website at [ www.celgene.com ].

This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Companya™s control. The Companya™s actual results, performance, or achievements could be materially different from those projected by these forward-looking statements.The factors that could cause actual results, performance, or achievements to differ from the forward-looking statements are discussed in the Companya™s filings with the Securities and Exchange Commission, such as the Companya™s Form 10-K, 10-Q and 8-K reports.Given these risks and uncertainties, you are cautioned not to place undue reliance on the forward-looking statements.